Cryptotanshinone Inhibits Bladder Cancer Cell Malignant Progression in a Lipopolysaccharide-Induced Inflammatory Microenvironment through NLRP3 Inhibition

Figure 7

NLRP3 overexpression reversed cryptotanshinone (CTS)-reduced lipopolysaccharide (LPS)-induced bladder cancer cell malignant behaviors. In total, 5,637 cells were grown and pretreated with LPS, then transfected with pcDNA3.1-NLRP3 or vector-only as a negative control, and finally treated with CTS before being subjected to the (a) CCK-8 assay, (b and c) colony formation assay, (d and e) transwell invasion assay, (f and g) wound healing assay, and (h and i) Western blot analysis of cyclin D1, CDK4, MMP-2, MMP-9, E-cadherin, and vimentin proteins. NC, negative control; OE, overexpression. , , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)